Selecta Biosciences (NASDAQ:SELB) Announces Earnings Results, Misses Estimates By $0.10 EPS

Selecta Biosciences (NASDAQ:SELB) released its quarterly earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.10), MarketWatch Earnings reports.

Shares of Selecta Biosciences stock traded up $0.05 on Friday, reaching $2.98. 824,913 shares of the company were exchanged, compared to its average volume of 1,621,164. Selecta Biosciences has a fifty-two week low of $1.47 and a fifty-two week high of $5.70. The firm has a market capitalization of $337.32 million, a price-to-earnings ratio of -3.59 and a beta of 1.18. The stock has a fifty day moving average price of $3.79 and a 200-day moving average price of $3.71.

A number of research firms recently commented on SELB. William Blair upgraded shares of Selecta Biosciences from a “market perform” rating to an “outperform” rating in a research note on Thursday, March 18th. Zacks Investment Research cut Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 9th. HC Wainwright restated a “buy” rating on shares of Selecta Biosciences in a report on Monday, May 3rd. Finally, Mizuho raised Selecta Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $2.50 to $8.00 in a report on Tuesday, January 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $7.20.

In related news, COO Lloyd P. Johnston sold 15,128 shares of the firm’s stock in a transaction that occurred on Wednesday, March 17th. The shares were sold at an average price of $4.45, for a total value of $67,319.60. Following the completion of the transaction, the chief operating officer now owns 87,477 shares of the company’s stock, valued at approximately $389,272.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Timothy C. Barabe acquired 10,000 shares of the stock in a transaction on Friday, March 26th. The shares were purchased at an average price of $4.10 per share, for a total transaction of $41,000.00. Following the completion of the transaction, the director now owns 181,013 shares in the company, valued at approximately $742,153.30. The disclosure for this purchase can be found here. Company insiders own 22.40% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses.

Recommended Story: Consumer Price Index (CPI)

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with's FREE daily email newsletter.